This is not the most recent version of the article. View current version (2 MAY 2014)

Intervention Review

Carbamazepine for schizophrenia and schizoaffective psychoses

  1. S Leucht,
  2. J McGrath,
  3. P White,
  4. W Kissling

Editorial Group: Cochrane Schizophrenia Group

Published Online: 22 JUL 2002

DOI: 10.1002/14651858.CD001258


How to Cite

Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD001258. DOI: 10.1002/14651858.CD001258.

Author Information

*Dr Stefan Leucht, Oberarzt, Klinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar der TU-München, Ismaningerstr. 22, München, 81675, GERMANY. stefan.leucht@lrz.tum.de.

Publication History

  1. Published Online: 22 JUL 2002

SEARCH

This is not the most recent version of the article. View current version (02 MAY 2014)

 

Abstract

  1. Top of page
  2. Abstract
  3. Synopsis

Background

Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment and various additional medications are used to promote additional response. The antiepileptic carbamazepine is one such drug.

Objectives

To review the effects of carbamazepine and its derivatives for the treatment of schizophrenia and schizoaffective psychoses.

Search strategy

We searched Biological Abstracts (1980-2001), The Cochrane Library (Issue 3, 2001), The Cochrane Schizophrenia Group's Register of Trials (December 2001), EMBASE (1980-2001), MEDLINE (1966-2001), PsycLIT (1886-2001) and PSYNDEX (1974-2001). Citations from included trials were also inspected and relevant companies and authors contacted for additional data.

Selection criteria

All randomised controlled trials comparing carbamazepine or compounds of the carbamazepine family to placebo or no intervention, whether as sole treatment or as an adjunct to antipsychotic medication for the treatment of schizophrenia and/or schizoaffective psychoses.

Data collection and analysis

Citations and, where possible, abstracts were independently inspected by reviewers, papers ordered, re-inspected and quality assessed. Data were extracted independently by at least two reviewers. Dichotomous data were analysed using relative risks (RR) and the 95% confidence interval (CI) estimated. Where possible the number needed to treat (NNT) or number needed to harm statistics were calculated.

Main results

Ten studies with a total of 258 participants were included. One study comparing carbamazepine with placebo as the sole treatment for schizophrenia (n=31) was stopped early due to high relapse rate. No effect of carbamazepine was evident (RR relapse 4.1 CI 0.8 to 1.5). Another study (n=38) compared carbamazepine with antipsychotics as the sole treatment for schizophrenia. No differences in terms of mental state were found (RR 50% BPRS reduction 1.2 CI 0.8 to 1.9). More people who received the antipsychotic (perphenazine) had parkinsonism (RR 0.03 CI 0.00 to 0.04, NNH 1 CI 0.9 to 1.4). Eight studies compared adjunctive carbamazepine plus antipsychotics versus placebo plus antipsychotics. Adding carbamazepine was as acceptable as adding placebo (n=182, RR leaving the study early 0.5 CI 0.2 to 1.4). Carbamazepine augmentation of antipsychotics was superior compared with antipsychotics alone in terms of overall improvement, but participant numbers were low (2 RCTs, n=38, RR 0.6 CI 0.4 to 0.9, NNT 2 CI 1 to 5). There were no differences for mental state outcomes (6 RCTs n=147, RR 50% BPRS reduction 0.9 CI 0.7 to 1.1). Less people in the carbamazepine augmentation group had movement disorders than those taking haloperidol alone (1 RCT, n=20, RR 0.4 CI 0.1 to 1.0). The effects of carbamazepine on subgroups of people with schizophrenia and aggressive behaviour, negative symptoms or EEG abnormalities or with schizoaffective disorder are unknown.

Authors' conclusions

Based on currently available randomised trial-derived evidence, carbamazepine cannot be recommend for routine clinical use for treatment or augmentation of antipsychotic treatment of schizophrenia. At present large, simple well-designed and reported trials are justified especially if focusing on those with violent episodes and people with schizoaffective disorders or on those with both schizophrenia and EEG abnormalities.

 

Synopsis

  1. Top of page
  2. Abstract
  3. Synopsis

Plain language summary

Carbamazepine is an antiepileptic drug, which is also used as an adjunct to antipsychotics for schizophrenia. Although the original patient data from eight out of ten included studies could be re-analysed, no significant benefit of carbamazepine, either as a sole treatment or as an adjunct to antipsychotics, was found. However, as the total number of patients included was small, further randomised trials seem to be warranted.